BOCOM INTL: Raises target price for SKB BIO (06990) to HKD 642, maintains "Buy" rating.
Kelun-Botais product sales in the first half of the year exceeded expectations, with accelerating investments in commercialization and R&D. Sac-TMT is making comprehensive inroads into the 1L NSCLC field.
BOCOM INTL released a research report stating that it has raised the target price for SKB BIO (06990) to HKD 642 and maintained a "Buy" rating. The report indicated that SKB BIO's product sales in the first half of the year exceeded expectations, with commercialization and R&D investments continuing to accelerate. Sac-TMT has made significant strides into the 1L NSCLC field, and the prototype of the next-generation antibody-drug conjugate matrix is beginning to take shape.
Related Articles
BINJIANG SER (03316) announced its interim results, with a net profit attributable to equity shareholders of approximately 315 million yuan, an increase of 5.8% year-on-year.
Liu Liu Mei (06658) announced its interim results, with a shareholder profit of 141 million yuan, an increase of 33.46% year-on-year.
PINESTONE (00804) has appointed Liu Hongwei as a non-executive director and co-chairman.
BINJIANG SER (03316) announced its interim results, with a net profit attributable to equity shareholders of approximately 315 million yuan, an increase of 5.8% year-on-year.
Liu Liu Mei (06658) announced its interim results, with a shareholder profit of 141 million yuan, an increase of 33.46% year-on-year.
PINESTONE (00804) has appointed Liu Hongwei as a non-executive director and co-chairman.
RECOMMEND
